Journal of Virus Eradication, 2017; 3: 168–184 Daily use of co-formulated tenofovir and emtricitabine for HIV pre-exposure prophylaxis (PrEP) by populations at high risk of HIV infection is now recommended in guidelines from the United States, Europe and Australia and globally through the 2015 WHO guidelines. These 2017 Australasian Society for HIV, Viral Hepatitis and Sexual Health Medicine‘s...
SHINE SA, July 2017 Today, July 28th, is World Hepatitis Day. There are no ‘healthy carriers’ of hepatitis B! SA Health & SHINE SA are promoting a 6-minute video providing advice for general practitioners in diagnosing, managing and contact tracing patients with chronic hepatitis B (CHB), to assist in preventing serious liver disease. It is now known that people who were...
National Institute of Allergy and Infectious Diseases (NIAID), July 24, 2017 A nine-year-old South African child who was diagnosed with HIV infection at one month of age and received anti-HIV treatment during infancy has suppressed the virus without anti-HIV drugs for eight and a half years, scientists reported today at the 9th IAS Conference on HIV Science in Paris. This case appears to be the...
ABC, 22nd July 2017 Despite the messaging around safe sex and unwanted pregnancies that dominates our discussion of sexual health, a growing number of Australians are opting to risk it. A recent study out of Monash University suggests the use of so-called natural contraception methods, like withdrawal and fertility awareness, are making a comeback. Sara Holton, a research fellow at Monash and co...
BBC news, 11 May 2017 Young people on the latest HIV drugs now have near-normal life expectancy because of improvements in treatments, a new study in The Lancet suggests. Twenty-year-olds who started antiretroviral therapy in 2010 are projected to live 10 years longer than those first using it in 1996, it found. Doctors say that starting treatment early is crucial to achieve a long and healthy...
Poz, USA, March 2017 The National Alliance of State & Territorial AIDS Directors (NASTAD) released its own statement regarding the risk of sexual transmission of HIV from people who are virally suppressed. The statement affirms that “durably virally suppressed people living with HIV on antiretroviral therapy do not sexually transmit the virus.” It describes virally suppressed as “having a...